Posts tagged Bausch
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $1.0 billion aggregate principal amount of new senior secured notes due 2027 (the "Notes"). As previously announced, the Company is also seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the "New Term B Loans") and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur upon completion of the initial public offering ("IPO") of Bausch + Lomb Corporation ("Bausch + Lomb" and such offering, the "Bausch + Lomb IPO") and a related debt financing by Bausch + Lomb (the "Bausch + Lomb Debt Financing").

Read More
Bausch Health Launches ENVIVE™ Daily Probiotic Supplement

LAVAL, QC, April 8, 2021 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced the U.S. launch of its novel daily over-the-counter probiotic supplement, ENVIVE™. ENVIVE™ is shown to help reduce the severity and frequency of five occasional gastrointestinal (GI) symptoms - diarrhea, constipation, gas, bloating and discomfort - and help strengthen and protect the digestive system by strengthening the gut barrier. ENVIVE™ is proven to help relieve these occasional GI symptoms in as little as two weeks.*

Read More